

# **Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Pipeline Review, H1 2018**

<https://marketpublishers.com/r/B87C516BE22EN.html>

Date: January 2018

Pages: 53

Price: US\$ 3,500.00 (Single User License)

ID: B87C516BE22EN

## **Abstracts**

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Pipeline Review, H1 2018

### **SUMMARY**

According to the recently published report 'Bcl 2 Like Protein 1 - Pipeline Review, H1 2018'; Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Bcl-2-like protein 1 is a protein encoded by the BCL2L1 gene. It belongs to BCL-2 family. It is a potent inhibitor of cell death. It inhibits activation of caspases. It regulate cell death by blocking the voltage-dependent anion channel by binding to it and preventing the release of the caspase activator (CYC1) from the mitochondrial membrane. It acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis.

The report 'Bcl 2 Like Protein 1 - Pipeline Review, H1 2018' outlays comprehensive information on the Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in

Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Small-Cell Lung Cancer, Solid Tumor, Chronic Lymphocytic Leukemia (CLL), Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Leukemias, Metastatic Melanoma, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Myelofibrosis, Non-Small Cell Lung Cancer, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) and Post-Polycythemia Vera Myelofibrosis (PPV-MF).

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1)

The report reviews Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics and enlists all their major and minor projects

The report assesses Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Overview

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Therapeutics  
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Therapeutics  
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Companies  
Involved in Therapeutics Development

AbbVie Inc

Ascentage Pharma Group Corp Ltd

Merrimack Pharmaceuticals Inc

Takeda Pharmaceutical Co Ltd

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Drug Profiles

ABT-737 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APG-1252 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

navitoclax dihydrochloride - Drug Profile

Product Description

Mechanism Of Action

**R&D Progress****Small Molecule to Inhibit BCL2 and BCLX for Oncology - Drug Profile****Product Description****Mechanism Of Action****R&D Progress****Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology - Drug Profile****Product Description****Mechanism Of Action****R&D Progress****Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology and MRSA Infections - Drug Profile****Product Description****Mechanism Of Action****R&D Progress****WEHI-539 - Drug Profile****Product Description****Mechanism Of Action****R&D Progress****Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Dormant Products****Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Discontinued Products****Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Product Development Milestones****Featured News & Press Releases****Jun 26, 2017: Ascentage Announces CFDA Grants Bcl-2/Bcl-XL inhibitor APG-1252 IND Approval for Treatment of Cancers****Dec 26, 2016: Ascentage Announces FDA Grants Bcl-2/Bcl-XL inhibitor APG-1252 IND Approval for Treatment of Cancers****Oct 13, 2016: Ascentage Pharma takes a leading position in novel drug development targeting dual pathways of apoptosis and autophagy****Apr 22, 2013: Walter And Eliza Hall Institute Scientists And Their Collaborators Develop New Potential Anti-cancer Compound WEHI-539****Nov 16, 2011: New Drug Combo Targets Multiple Cancers****Jun 01, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 ASCO Annual Meeting****Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results From Clinical Trials Of AT-101 In Prostate, Brain, And Lung Cancers At 2009 Asco Annual Meeting****Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results**

From Clinical Trials Of AT-101 In Prostate, Brain, And Lung cancers At 2009 Asco Annual Meeting

May 26, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 Asco Annual Meeting

May 26, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 ASCO Annual Meeting

Feb 27, 2009: Ascenta Therapeutics Announces Positive Preliminary Results With AT-101 In Docetaxel Refractory Prostate Cancer

Feb 23, 2007: Ascenta Therapeutics Presents New Clinical Data On AT-101 Monotherapy for the Treatment of Hormone-Refractory Prostate Cancer

Jan 26, 2007: Abbott And Genentech Announce Global, Integrated Research, Development And Commercialization Collaboration In Oncology

Dec 10, 2006: Ascenta Therapeutics Presents New Clinical and Biological Data on AT-101 for the Treatment of Chronic Lymphocytic Leukemia

Jun 05, 2006: Clinical Data On Ascenta Therapeutics Lead Product AT-101 Presented At The 2006 American Society For Clinical Oncology Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by AbbVie Inc, H1 2018

Pipeline by Ascentage Pharma Group Corp Ltd, H1 2018

Pipeline by Merrimack Pharmaceuticals Inc, H1 2018

Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd.1), H1 2018

Dormant Products, H1 2018 (Contd.2), H1 2018

Discontinued Products, H1 2018

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

### COMPANIES MENTIONED

AbbVie Inc

Ascentage Pharma Group Corp Ltd

Merrimack Pharmaceuticals Inc

Takeda Pharmaceutical Co Ltd



## I would like to order

Product name: Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/B87C516BE22EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B87C516BE22EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

